PCSK9 inhibitors and cardiovascular events

New England Journal of Medicine

Volumn 373, Issue 8, 2015, Pages 773-775

  Auer, Johann ^a   Berent, Robert ^b   Primus, Carina ^a  

^a St Josef Hospital Braunau   (Austria)

^b Center for Cardiovascular Rehabilitation   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN PCSK9; SERINE PROTEINASE; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY;

CARDIOVASCULAR DISEASE; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LETTER; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; BLOOD; CARDIOVASCULAR DISEASES; FEMALE; MALE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE;

EID: 84939786809     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1508222     Document Type: Letter

References (5)

1. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99.
2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-934.
3. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-13.
4. Mills EJ, O'Regan C, Eyawo O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: A meta-analysis of >40 000 patients. Eur Heart J 2011; 32: 1409-15.
5. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.